**Suppl. Table 1a.** Other findings from immunological assessment in patient 1 receiving inhibiting immune-suppression therapy.

| Parameter       | Time | D | Mean | SD  | p-value* | Median | Minimum | Maximum | p-value** |
|-----------------|------|---|------|-----|----------|--------|---------|---------|----------|
| CD8(n)          | Basal| 2 | 476.0| 33.9| 0.354    | 476.0  | 452.0  | 500.0  | 0.248    |
|                 | IT   | 3 | 534.0| 66.9|          | 508.0  | 484.0  | 610.0  |          |
| NK(n)           | Basal| 2 | 215.0| 15.6| 0.380    | 215.0  | 204.0  | 226.0  | 0.374    |
|                 | IT   | 3 | 184.0| 39.0|          | 177.0  | 149.0  | 226.0  |          |
| Treg(n)         | Basal| 2 | 19.0 | 5.7 | 0.329    | 19.0   | 15.0   | 23.0   | 0.083    |
|                 | IT   | 3 | 25.6 | 2.0 |          | 25.0   | 24.0   | 27.9   |          |
| CD4+45R0(n)     | Basal| 2 | 364.5| 44.5| 0.222    | 364.5  | 333.0  | 396.0  | 0.083    |
|                 | IT   | 3 | 519.3| 131.5|         | 493.0  | 403.0  | 662.0  |          |
| IL1(pg/ml)      | Basal| 2 | 1.2  | 0.9 | 0.448    | 1.2    | 0.5    | 1.8    | 0.374    |
|                 | IT   | 3 | 1.9  | 0.3 |          | 1.8    | 1.7    | 2.2    |          |
| IL1R(pg/ml)     | Basal| 2 | 330.0| 14.1| 0.024    | 330.0  | 320.0  | 340.0  | 0.083    |
|                 | IT   | 3 | 464.3| 41.2|          | 478.0  | 418.0  | 497.0  |          |
| IL6(pg/ml)      | Basal| 2 | 8.0  | 6.5 | 0.433    | 8.0    | 3.4    | 12.6   | 0.248    |
|                 | IT   | 3 | 2.4  | 1.7 |          | 2.7    | 0.6    | 4.0    |          |
| IL8(pg/ml)      | Basal| 2 | 1.8  | 1.6 | 0.234    | 1.8    | 0.6    | 2.9    | 0.083    |
|                 | IT   | 3 | 5.2  | 2.9 |          | 3.8    | 3.3    | 8.6    |          |
| IL10(pg/ml)     | Basal| 2 | 2.2  | 0.1 | 0.096    | 2.2    | 2.1    | 2.3    | 0.083    |
|                 | IT   | 3 | 2.6  | 0.2 |          | 2.6    | 2.4    | 2.8    |          |
| IL2R(ng/ml)     | Basal| 2 | 2.8  | 0.1 | 0.395    | 2.8    | 2.7    | 2.9    | 0.197    |
|                 | IT   | 3 | 2.7  | 0.1 |          | 2.7    | 2.6    | 2.7    |          |
| TNFalpha(pg/ml) | Basal| 2 | 5.8  | 4.0 | 0.681    | 5.8    | 3.0    | 8.6    | 1.000    |
|                 | IT   | 3 | 4.3  | 0.9 |          | 4.7    | 3.2    | 4.9    |          |
| TGFbeta1(pg/ml) | Basal| 2 | 67.5 | 19.1| 0.689    | 67.5   | 54.0   | 81.0   | 1.000    |
|                 | IT   | 3 | 60.3 | 2.5 |          | 60.0   | 58.0   | 63.0   |          |
| FGF(pg/ml)      | Basal| 2 | 8.2  | 3.0 | 0.538    | 8.2    | 6.1    | 10.3   | 0.564    |
|                 | IT   | 3 | 6.7  | 2.1 |          | 6.6    | 4.6    | 8.8    |          |
| EGF(pg/ml)      | Basal| 2 | 21.5 | 2.1 | 0.028    | 21.5   | 20.0   | 23.0   | 0.083    |
|                 | IT   | 3 | 11.3 | 3.1 |          | 12.0   | 8.0    | 14.0   |          |
| IGF1(pg/ml)     | Basal| 2 | 121.5| 0.7 | 0.585    | 121.5  | 121.0  | 122.0  | 0.564    |
|                 | IT   | 3 | 120.3| 2.5 |          | 120.0  | 118.0  | 123.0  |          |
| PDGF(pg/ml)     | Basal| 2 | 1066.5| 429.2| 0.341    | 1066.5 | 763.0  | 1370.0 | 0.083    |
|                 | IT   | 3 | 577.3| 143.3|          | 655.0  | 412.0  | 665.0  |          |
| MCP-1(pg/ml)    | Basal| 2 | 250.5| 33.2| 0.058    | 250.5  | 227.0  | 274.0  | 0.083    |
|                 | IT   | 3 | 467.7| 94.7|          | 444.0  | 387.0  | 572.0  |          |

D: determination; IT: inhibiting immune-suppression therapy; Ly tot: total lymphocytes; CD8, CD4+25+(Treg), CD4+45R0 (memory cells); monoclonal antibody T subsets; NK; CD16+56+; natural killer cells; IL: interleukin; IL1R: interleukin 1 receptor; IL2R: interleukin 2 receptor; TNFalpha: tumor necrosis factor alpha; TGFbeta1:tumor growth factor beta1; FGF: fibroblast growth factor; EGF: epidermal growth factor; IGF1: insulin-like growth factor-1; PDGF: platelet-derived growth factor; MCP-1: monocyte chemo-attractant protein-1; *t-test; **Mann-Whitney test
**Suppl. Table 1b.** Other findings from immunological assessment in patient 2 receiving inhibiting immunosuppression therapy.

| Parameter | Time | D | Mean | SD | p-value* | Median (pg/ml) | Minimum (pg/ml) | Maximum (pg/ml) | p-value** |
|-----------|------|---|------|----|----------|----------------|-----------------|----------------|-----------|
| Ly tot(n) | Basal | 2 | 1141.0 | 54.0 | 0.576 | 1141.5 | 1103.0 | 1180.0 | 0.564 |
|           | IT   | 3 | 1174.0 | 59.0 |            | 1146.0 | 1135.0 | 1242.0 |            |
| CD4(n)    | Basal | 2 | 639.0 | 29.7 | 0.297 | 639.0 | 618.0 | 660.0 | 0.564 |
|           | IT   | 3 | 660.3 | 8.7  |            | 658.0 | 653.0 | 670.0 |            |
| CD8(n)    | Basal | 2 | 171.0 | 8.5  | 0.818 | 171.0 | 165.0 | 177.0 | 0.564 |
|           | IT   | 3 | 176.7 | 29.7 |            | 160.0 | 159.0 | 211.0 |            |
| CD3(n)    | Basal | 2 | 856.0 | 41.0 | 0.498 | 856.0 | 827.0 | 885.0 | 0.564 |
|           | IT   | 3 | 884.5 | 40.3 |            | 863.0 | 859.5 | 931.0 |            |
| NK(n)     | Basal | 2 | 165.5 | 16.3 | 0.728 | 165.5 | 154.0 | 177.0 | 0.564 |
|           | IT   | 3 | 160.5 | 13.3 |            | 160.0 | 147.5 | 174.0 |            |
| Treg (n)  | Basal | 2 | 36.0 | 2.8  | 0.011 | 36.0 | 34.0 | 38.0 | 0.076 |
|           | IT   | 3 | 25.0 | 1.7  |            | 26.0 | 23.0 | 26.0 |            |
| CD4+45R0(n) | Basal | 2 | 478.5 | 6.4  | 0.773 | 478.5 | 474.0 | 483.0 | 1.000 |
|           | IT   | 3 | 466.3 | 51.6 |            | 481.0 | 409.0 | 509.0 |            |
| CD19(n)   | Basal | 2 | 119.5 | 2.1  | 0.742 | 119.5 | 118.0 | 121.0 | 0.564 |
|           | IT   | 3 | 117.7 | 6.7  |            | 116.0 | 112.0 | 125.0 |            |
| IL1(pg/ml)| Basal | 2 | 3.8  | 3.2  | 0.359 | 3.8  | 1.5  | 6.0  | 0.083 |
|           | IT   | 3 | 0.2  | 0.3  |            | 116.0 | 112.0 | 125.0 |            |
| IL1R(pg/ml) | Basal | 2 | 355.5 | 47.4 | 0.032 | 355.5 | 322.0 | 389.0 | 0.083 |
|           | IT   | 3 | 200.3 | 43.4 |            | 181.0 | 170.0 | 250.0 |            |
| IL6(pg/ml)| Basal | 2 | 7.5  | 7.0  | 0.824 | 7.5  | 2.5  | 12.4 | 1.000 |
|           | IT   | 3 | 6.0  | 2.2  |            | 6.4  | 3.7  | 8.0  |            |
| IL8(pg/ml)| Basal | 2 | 1.0  | 0.1  | 0.008 | 1.0  | 0.9  | 1.0  | 0.076 |
|           | IT   | 3 | 0.1  | 0.2  |            | 0.0  | 0.0  | 0.3  |            |
| IL10(pg/ml)| Basal | 2 | 1.7  | 0.5  | 0.911 | 1.7  | 1.3  | 2.0  | 0.564 |
|           | IT   | 3 | 1.8  | 1.2  |            | 1.1  | 1.0  | 3.2  |            |
| IL2R(nM) | Basal | 2 | 3.5  | 0.2  | 0.584 | 3.5  | 3.3  | 3.6  | 0.564 |
|           | IT   | 3 | 3.7  | 0.5  |            | 3.7  | 3.2  | 4.1  |            |
| TNFa(alpha) (pg/ml) | Basal | 2 | 7.0  | 0.3  | 0.321 | 7.0  | 6.8  | 7.2  | 0.083 |
|           | IT   | 3 | 12.9 | 6.6  |            | 9.6  | 8.5  | 20.5 |            |
| TGFB1(pg/ml) | Basal | 2 | 63.1 | 0.1  | 0.962 | 63.1 | 63.0 | 63.2 | 0.564 |
|           | IT   | 3 | 61.6 | 40.2 |            | 40.0 | 36.7 | 108.0 |            |
| FGF(pg/ml)| Basal | 2 | 2.2  | 0.8  | 0.485 | 63.1 | 63.0 | 63.2 | 0.248 |
|           | IT   | 3 | 1.4  | 2.2  |            | 1.2  | 0.3  | 2.7  |            |
| EGF(pg/ml)| Basal | 2 | 21.0 | 12.7 | 0.459 | 21.0 | 12.0 | 30.0 | 0.564 |
|           | IT   | 3 | 45.3 | 37.5 |            | 45.0 | 8.0 | 83.0 |            |
| IGFl(nM) | Basal | 2 | 164.5 | 10.6 | 0.030 | 164.5 | 157.0 | 172.0 | 0.083 |
|           | IT   | 3 | 196.0 | 7.8  |            | 192.0 | 191.0 | 205.0 |            |
| PDGF(pg/ml)| Basal | 2 | 5607.5 | 2527.9 | 0.901 | 5607.5 | 3820.0 | 7395.0 | 1.000 |
|           | IT   | 3 | 5903.3 | 2324.6 |            | 5495.0 | 3810.0 | 8405.0 |            |
| VEGF(pg/ml)| Basal | 2 | 207.5 | 70.0  | 0.638 | 207.5 | 158.0 | 257.0 | 0.564 |
|           | IT   | 3 | 164.7 | 98.6 |            | 152.0 | 73.0 | 269.0 |            |
| MCP-1(pg/ml) | Basal | 2 | 516.5 | 67.2  | 0.573 | 516.5 | 469.0 | 564.0 | 0.554 |
|           | IT   | 3 | 468.3 | 90.6 |            | 416.0 | 416.0 | 573.0 |            |

D: determination; IT: inhibiting immune-suppression therapy; Ly tot: total lymphocytes; CD3, CD4, CD8, CD4+25+ (Treg), CD4+45R0 (memory cells): monoclonal antibody T subsets; NK: CD16+56+ natural killer cells; CD19: monoclonal antibody B lymphocytes; IL: interleukin; IL1R: interleukin 1 receptor; IL2R: interleukin 2 receptor; TNFa: tumor necrosis factor alpha; TGFB1: tumor growth factor beta1; FGF: fibroblast growth factor; EGF: epidermal growth factor; IGFl: insulin-like growth factor-1; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth; MCP-1: monocyte
**Suppl. Table 1c.** Other findings from immunological assessment in patient 3 receiving inhibiting immune-suppression therapy.

| Parameter       | Time  | D | Mean | SD | p-value* | Median | Minimum | Maximum | p-value** |
|-----------------|-------|---|------|----|----------|--------|---------|---------|----------|
| Ly tot(n)       | Basale| 2 | 1380.0 | 17.0 | 0.984    | 1380.0 | 1368.0 | 1392.0 | 0.564    |
|                 | IT    | 3 | 1383.0 | 188.0 |          | 1428.0 | 1177.0 | 1544.0 |          |
| CD8(n)          | Basale| 2 | 282.5   | 6.4   | 0.723    | 282.5  | 278.0  | 287.0  | 0.564    |
|                 | IT    | 3 | 271.7   | 37.0   |          | 271.0  | 235.0  | 309.0  |          |
| CD3(n)          | Basale| 2 | 958.5   | 2.1   | 0.354    | 958.5  | 957.0  | 960.0  | 0.139    |
|                 | IT    | 3 | 907.0   | 63.2   |          | 928.0  | 836.0  | 957.0  |          |
| NK(n)           | Basale| 2 | 110.0   | 1.4   | 0.612    | 110.0  | 109.0  | 111.0  | 0.564    |
|                 | IT    | 3 | 126.3   | 38.8   |          | 143.0  | 82.0   | 154.0  |          |
| Treg(n)         | Basale| 2 | 34.3    | 0.1   | 0.759    | 34.3   | 34.2   | 34.3   | 0.564    |
|                 | IT    | 3 | 35.0    | 3.0    |          | 35.0   | 32.0   | 38.0   |          |
| CD4+45R0        | Basale| 2 | 345.0   | 4.2   | 0.299    | 345.0  | 342.0  | 348.0  | 0.083    |
|                 | IT    | 3 | 459.3   | 122.4  |          | 401.0  | 377.0  | 600.0  |          |
| CD19(n)         | Basale| 2 | 303.5   | 3.5   | 0.530    | 303.5  | 301.0  | 306.0  | 0.564    |
|                 | IT    | 3 | 349.3   | 86.8   |          | 357.0  | 259.0  | 432.0  |          |
| IL1(pg/ml)      | Basale| 2 | 0.2     | 0.2    | 0.112    | 0.2    | 0.0    | 0.3    | 0.083    |
|                 | IT    | 3 | 0.8     | 0.4    |          | 0.9    | 0.4    | 1.1    |          |
| IL1R(pg/ml)     | Basale| 2 | 284.5   | 318.9  | 0.593    | 284.5  | 59.0   | 510.0  | 1.000    |
|                 | IT    | 3 | 451.7   | 47.5   |          | 450.0  | 405.0  | 500.0  |          |
| IL6(pg/ml)      | Basale| 2 | 1.3     | 0.1    | 0.538    | 1.3    | 1.2    | 1.4    | 0.564    |
|                 | IT    | 3 | 1.7     | 0.8    |          | 2.0    | 0.8    | 2.4    |          |
| IL8(pg/ml)      | Basale| 2 | 0.6     | 0.6    | 0.374    | 0.6    | 0.2    | 1.0    | 0.374    |
|                 | IT    | 3 | 0.2     | 0.3    |          | 0.2    | 0.0    | 0.5    |          |
| IL10(pg/ml)     | Basale| 2 | 1.9     | 0.5    | 0.619    | 1.9    | 1.5    | 2.2    | 0.564    |
|                 | IT    | 3 | 2.2     | 0.9    |          | 2.4    | 1.3    | 3.0    |          |
| IL12(pg/ml)     | Basale| 2 | 132.0   | 21.2   | 0.758    | 132.0  | 117.0  | 147.0  | 1.000    |
|                 | IT    | 3 | 126.0   | 6.2    |          | 124.0  | 121.0  | 133.0  |          |
| IL2R(nG/ml)     | Basale| 2 | 1.6     | 0.1    | 0.550    | 1.6    | 1.5    | 1.7    | 0.361    |
|                 | IT    | 3 | 1.7     | 0.2    |          | 1.8    | 1.5    | 1.8    |          |
| TNFalpha(pg/ml) | Basale| 2 | 4.9     | 2.7    | 0.901    | 4.9    | 3.0    | 6.8    | 1.000    |
|                 | IT    | 3 | 4.6     | 0.7    |          | 5.0    | 3.8    | 5.0    |          |
| TGF1(pg/ml)     | Basale| 2 | 21.8    | 1.9    | 0.079    | 21.8   | 20.4   | 23.1   | 0.083    |
|                 | IT    | 3 | 39.7    | 9.1    |          | 41.1   | 30.0   | 48.0   |          |
| FGF(pg/ml)      | Basale| 2 | 3.1     | 0.0    | 0.038    | 3.1    | 3.1    | 3.1    | 0.076    |
|                 | IT    | 3 | 3.8     | 0.3    |          | 3.7    | 3.6    | 4.1    |          |
| EGF(pg/ml)      | Basale| 2 | 4.0     | 4.2    | 0.272    | 4.0    | 1.0    | 7.0    | 0.197    |
|                 | IT    | 3 | 10.0    | 5.2    |          | 7.0    | 7.0    | 16.0   |          |
| IGFI(pg/ml)     | Basale| 2 | 202.5   | 12.0   | 0.061    | 202.5  | 194.0  | 211.0  | 0.083    |
|                 | IT    | 3 | 166.3   | 14.2   |          | 174.0  | 150.0  | 175.0  |          |
| PDGF(pg/ml)     | Basale| 2 | 880.5   | 391.0  | 0.718    | 880.5  | 604.0  | 1157.0 | 0.564    |
|                 | IT    | 3 | 1064.7  | 558.7  |          | 820.0  | 670.0  | 1704.0 |          |
| MCP-1(pg/ml)    | Basale| 2 | 399.5   | 12.0   | 0.345    | 399.5  | 391.0  | 408.0  | 0.564    |
|                 | IT    | 3 | 333.3   | 78.9   |          | 311.0  | 268.0  | 421.0  |          |

D: determination; IT: inhibiting immune-suppression therapy; Ly tot: total lymphocytes; CD3, CD8, CD4+25+(Treg). CD4+45R0 (memory cells): monoclonal antibody T subsets; NK: CD16+56+. natural killer cells; CD19: monoclonal antibody B lymphocytes; IL: interleukin; IL1R: interleukin 1 receptor; IL2R: interleukin 2 receptor; TNFalpha: tumor necrosis factor alpha; TGF1: tumor growth factor beta1; FGF: fibroblast growth factor; EGF: epidermal growth factor; IGFI: insulin-like growth factor 1; PDGF: platelet-derived growth factor; MCP-1: monocyte chemo-attractant protein-1; * t-test; ** Mann-Whitney test.
test
### Suppl. Table 1d. Other findings from immunological assessment in patient 4 receiving inhibiting immune-suppression therapy.

| Patient 4 | \multicolumn{7}{c|}{Parameter} | \multicolumn{2}{c|}{Time} | D Mean | SD | p-value* | Median | Minimum | Maximum | p-value** |
|-----------|----------------|-----------------|------------|-------|----------|--------|--------|--------|----------|--------|--------|--------|--------|
| \(\text{CD}4(n)\) | \multicolumn{4}{c|}{Basale} | 3 | 641.0 | 39.9 | 0.190 | 661.0 | 595.0 | 667.0 | 0.127 |
|          | \multicolumn{4}{c|}{IT} | 3 | 573.7 | 62.1 |          | 555.0 | 523.0 | 643.0 |          |
| \(\text{NK(n)}\) | \multicolumn{4}{c|}{Basale} | 3 | 330.3 | 109.7 | 0.324 | 345.0 | 214.0 | 432.0 | 0.275 |
|          | \multicolumn{4}{c|}{IT} | 3 | 249.7 | 58.2 |          | 266.0 | 185.0 | 298.0 |          |
| \(\text{TREG(n)}\) | \multicolumn{4}{c|}{Basale} | 3 | 33.3 | 13.3 | 0.708 | 30.0 | 22.0 | 48.0 | 0.827 |
|          | \multicolumn{4}{c|}{IT} | 3 | 28.8 | 14.1 |          | 33.5 | 13.0 | 40.0 |          |
| \(\text{CD}4+45R0(n)\) | \multicolumn{4}{c|}{Basale} | 3 | 350.3 | 126.2 | 0.212 | 374.0 | 214.0 | 463.0 | 0.275 |
|          | \multicolumn{4}{c|}{IT} | 3 | 235.3 | 45.6 |          | 247.0 | 185.0 | 274.0 |          |
| \(\text{IL}1(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 1.0 | 0.6 | 0.300 | 0.7 | 0.6 | 1.7 | 0.050 |
|          | \multicolumn{4}{c|}{IT} | 3 | 5.6 | 5.8 |          | 2.8 | 1.8 | 12.3 |          |
| \(\text{IL}1R(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 171.3 | 65.7 | 0.217 | 157.0 | 114.0 | 243.0 | 0.275 |
|          | \multicolumn{4}{c|}{IT} | 3 | 112.7 | 22.2 |          | 125.0 | 87.0 | 126.0 |          |
| \(\text{IL}6(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 11.1 | 12.8 | 0.396 | 4.0 | 3.4 | 25.9 | 0.513 |
|          | \multicolumn{4}{c|}{IT} | 3 | 19.0 | 2.5 |          | 20.3 | 16.1 | 20.7 |          |
| \(\text{IL}8(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 3.1 | 0.9 | 0.898 | 3.2 | 2.2 | 4.0 | 0.507 |
|          | \multicolumn{4}{c|}{IT} | 3 | 2.7 | 4.7 |          | 0.0 | 0.0 | 8.2 |          |
| \(\text{IL}10(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 5.4 | 7.5 | 0.196 | 1.6 | 0.6 | 14.0 | 0.275 |
|          | \multicolumn{4}{c|}{IT} | 3 | 18.7 | 12.9 |          | 12.0 | 10.6 | 33.6 |          |
| \(\text{IL}12(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 81.0 | 39.8 | 0.155 | 58.0 | 58.0 | 127.0 | 0.178 |
|          | \multicolumn{4}{c|}{IT} | 3 | 127.0 | 22.0 |          | 127.0 | 105.0 | 149.0 |          |
| \(\text{IL}2R(\text{ng/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 3.4 | 2.9 | 0.123 | 1.8 | 1.7 | 6.7 | 0.077 |
|          | \multicolumn{4}{c|}{IT} | 3 | 7.5 | 0.8 |          | 7.6 | 6.7 | 8.2 |          |
| \(\text{TNFalpha(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 6.1 | 4.3 | 0.662 | 4.4 | 2.9 | 11.0 | 0.513 |
|          | \multicolumn{4}{c|}{IT} | 3 | 7.5 | 2.6 |          | 7.1 | 5.1 | 10.2 |          |
| \(\text{TGF}B1(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 34.9 | 6.8 | 0.506 | 36.0 | 27.6 | 41.0 | 0.658 |
|          | \multicolumn{4}{c|}{IT} | 3 | 41.3 | 13.8 |          | 36.0 | 31.0 | 57.0 |          |
| \(\text{FGF(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 1.8 | 1.2 | 0.308 | 2.2 | 0.4 | 2.8 | 0.513 |
|          | \multicolumn{4}{c|}{IT} | 3 | 2.8 | 0.7 |          | 2.7 | 2.1 | 3.5 |          |
| \(\text{EGF(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 7.7 | 5.5 | 0.707 | 5.0 | 4.0 | 14.0 | 0.658 |
|          | \multicolumn{4}{c|}{IT} | 3 | 6.3 | 1.5 |          | 6.0 | 5.0 | 8.0 |          |
| \(\text{IGF1(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 117.3 | 14.2 | 0.101 | 125.0 | 101.0 | 126.0 | 0.050 |
|          | \multicolumn{4}{c|}{IT} | 3 | 139.0 | 10.5 |          | 138.0 | 129.0 | 150.0 |          |
| \(\text{PDGF(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 618.0 | 277.4 | 0.578 | 492.0 | 426.0 | 936.0 | 0.827 |
|          | \multicolumn{4}{c|}{IT} | 3 | 939.3 | 877.6 |          | 498.0 | 370.0 | 1950.0 |          |
| \(\text{VEGF(\text{pg/ml})}\) | \multicolumn{4}{c|}{Basale} | 3 | 77.7 | 30.7 | 0.201 | 74.0 | 49.0 | 110.0 | 0.275 |
|          | \multicolumn{4}{c|}{IT} | 3 | 49.0 | 10.8 |          | 52.0 | 37.0 | 58.0 |          |
| \(\text{MCP}-1(\text{pg/ml})\) | \multicolumn{4}{c|}{Basale} | 3 | 379.3 | 63.6 | 0.044 | 400.0 | 308.0 | 430.0 | 0.050 |
|          | \multicolumn{4}{c|}{IT} | 3 | 193.3 | 91.5 |          | 159.0 | 124.0 | 297.0 |          |

D: determination; IT: inhibiting immune-suppression therapy; Ly: tot. total lymphocytes; CD4: CD4+25+(Treg), CD4+45R0 (memory cells); monoclonal antibody T subsets; NK: CD16+56+. natural killer cells; IL: interleukin; IL1R: interleukin 1 receptor; IL2R: interleukin 2 receptor; TNFalpha: tumor necrosis factor alpha; TGFBI: tumor growth factor beta1; FGF: fibroblast growth factor; EGF: epidermal growth factor; IGFI: insulin-like growth factor-1; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; MCP-1: monocyte chemo-attractant protein-1; * t-test; **Mann-Whitney test